SG11201408150UA - Treatment of pluripotent cells - Google Patents

Treatment of pluripotent cells

Info

Publication number
SG11201408150UA
SG11201408150UA SG11201408150UA SG11201408150UA SG11201408150UA SG 11201408150U A SG11201408150U A SG 11201408150UA SG 11201408150U A SG11201408150U A SG 11201408150UA SG 11201408150U A SG11201408150U A SG 11201408150UA SG 11201408150U A SG11201408150U A SG 11201408150UA
Authority
SG
Singapore
Prior art keywords
international
johnson
rule
pluripotent cells
applicant
Prior art date
Application number
SG11201408150UA
Other languages
English (en)
Inventor
Janet Davis
Jiajian Liu
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of SG11201408150UA publication Critical patent/SG11201408150UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
SG11201408150UA 2012-06-14 2013-06-13 Treatment of pluripotent cells SG11201408150UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261741776P 2012-06-14 2012-06-14
PCT/US2013/045617 WO2013192005A2 (en) 2012-06-14 2013-06-13 Differentiation of human embryonic stem cells into pancreatic endocrine cells

Publications (1)

Publication Number Publication Date
SG11201408150UA true SG11201408150UA (en) 2015-01-29

Family

ID=49756254

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408150UA SG11201408150UA (en) 2012-06-14 2013-06-13 Treatment of pluripotent cells

Country Status (14)

Country Link
US (1) US20130337564A1 (pt)
EP (1) EP2861723A4 (pt)
JP (1) JP2015519085A (pt)
KR (1) KR20150030709A (pt)
CN (1) CN104603262A (pt)
AR (1) AR091457A1 (pt)
BR (1) BR112014031424A2 (pt)
CA (1) CA2876671A1 (pt)
MX (1) MX2014015419A (pt)
PH (1) PH12014502748A1 (pt)
RU (1) RU2015100900A (pt)
SG (1) SG11201408150UA (pt)
WO (1) WO2013192005A2 (pt)
ZA (1) ZA201500224B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
KR102580225B1 (ko) 2013-06-11 2023-09-20 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 SC-β 세포 및 조성물 그리고 그 생성 방법
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US10443042B2 (en) 2014-12-18 2019-10-15 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived beta cells and uses thereof
CN107614678B (zh) 2014-12-18 2021-04-30 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
US10190096B2 (en) 2014-12-18 2019-01-29 President And Fellows Of Harvard College Methods for generating stem cell-derived β cells and uses thereof
SG10202101478YA (en) * 2016-08-18 2021-03-30 Nat Univ Singapore Substituted azole derivatives for generation, proliferation and differentiation of hematopoietic stem and progenitor cells
US11591571B2 (en) 2016-11-16 2023-02-28 Cynata Therapeutics Limited Pluripotent stem cell assay
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
RU2019139434A (ru) 2017-05-05 2021-06-07 Сентр фор Проуб Девелопмент энд Коммерсиализэйшн Моноклональные антитела против igf-1r и их применение
CN111263747B (zh) 2017-05-05 2023-10-27 探针技术开发及商业化中心 双官能螯合物的药代动力学增强及其用途
KR101966523B1 (ko) * 2017-05-29 2019-04-05 차의과학대학교 산학협력단 오가노이드 배양을 위한 조성물 및 방법
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
EP3710021A4 (en) 2017-11-15 2021-08-11 Semma Therapeutics, Inc. COMPOSITIONS FOR THE MANUFACTURE OF ISLAND CELLS AND METHODS OF USE
KR20210018919A (ko) * 2018-06-08 2021-02-18 노파르티스 아게 약물 산물 효능을 측정하기 위한 세포-기반 분석
CA3108275A1 (en) 2018-08-10 2020-02-13 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
US10724052B2 (en) 2018-09-07 2020-07-28 Crispr Therapeutics Ag Universal donor cells
CN114375300A (zh) 2019-09-05 2022-04-19 克里斯珀医疗股份公司 通用供体细胞
CA3150233A1 (en) 2019-09-05 2021-03-11 Alireza Rezania UNIVERSAL DONOR CELLS
AU2021414617A1 (en) 2020-12-31 2023-08-10 Crispr Therapeutics Ag Universal donor cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060030042A1 (en) * 2003-12-19 2006-02-09 Ali Brivanlou Maintenance of embryonic stem cells by the GSK-3 inhibitor 6-bromoindirubin-3'-oxime
WO2007030870A1 (en) * 2005-09-12 2007-03-22 Es Cell International Pte Ltd Cardiomyocyte production
US8741643B2 (en) * 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
US8623648B2 (en) * 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
US7939322B2 (en) * 2008-04-24 2011-05-10 Centocor Ortho Biotech Inc. Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm

Also Published As

Publication number Publication date
JP2015519085A (ja) 2015-07-09
BR112014031424A2 (pt) 2017-06-27
RU2015100900A (ru) 2016-08-10
EP2861723A2 (en) 2015-04-22
KR20150030709A (ko) 2015-03-20
ZA201500224B (en) 2017-09-27
AR091457A1 (es) 2015-02-04
CA2876671A1 (en) 2013-12-27
WO2013192005A3 (en) 2014-03-13
WO2013192005A2 (en) 2013-12-27
US20130337564A1 (en) 2013-12-19
MX2014015419A (es) 2015-07-14
CN104603262A (zh) 2015-05-06
EP2861723A4 (en) 2016-01-20
PH12014502748A1 (en) 2015-02-02

Similar Documents

Publication Publication Date Title
SG11201408150UA (en) Treatment of pluripotent cells
SG11201408124PA (en) Differentiation of human embryonic stem cells into pancreatic endocrine cells
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201906161VA (en) Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
SG11201901628XA (en) Methods and compositions for spinal cord cells
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201806988UA (en) Improved differentiation method
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201907653QA (en) Compositions and methods for enhanced gene expression
SG11201406903SA (en) Cell culture compositions and methods for polypeptide production
SG11201408405WA (en) Engineered three-dimensional connective tissue constructs and methods of making the same
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201803169WA (en) Cellulase variants and polynucleotides encoding same
SG11201903428XA (en) Pluripotent stem cell assay
SG11201407819UA (en) Improved methods of cell culture for adoptive cell therapy
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201900753VA (en) A method of isolating mesenchymal stem cells from umbilical cord amniotic membrane using a cell culture medium
SG11201406963RA (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
SG11201407793TA (en) Compounds and compositions for modulating egfr activity
SG11201407561UA (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
SG11201807134RA (en) Transposon system and methods of use
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201808306PA (en) Treatment of cancer with tg02
SG11201900058YA (en) Method of generating mesenchymal stem cells and uses thereof